172 related articles for article (PubMed ID: 20469785)
21. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.
Lam HC; Chu CH; Wei MC; Keng HM; Lu CC; Sun CC; Lee JK; Chuang MJ; Wang MC; Tai MH
Exp Biol Med (Maywood); 2006 Jun; 231(6):1010-5. PubMed ID: 16741040
[TBL] [Abstract][Full Text] [Related]
22. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A;
Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk.
Boh M; Opolski G; Poredos P; Ceska R; Jezovnik M
Int Angiol; 2011 Aug; 30(4):366-74. PubMed ID: 21747355
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
25. How to reach LDL targets quickly in patients with diabetes or metabolic syndrome.
Leiter LA; Martineau P; de Teresa E; Farsang C; Gaw A; Gensini G; Langer A;
J Fam Pract; 2008 Oct; 57(10):661-8. PubMed ID: 18842192
[TBL] [Abstract][Full Text] [Related]
26. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
[TBL] [Abstract][Full Text] [Related]
27. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A;
Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187
[TBL] [Abstract][Full Text] [Related]
28. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
Rublee DA; Burke JP
Postgrad Med; 2010 Mar; 122(2):16-24. PubMed ID: 20203452
[TBL] [Abstract][Full Text] [Related]
29. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Erdine S; Ro YM; Tse HF; Howes LG; Aguilar-Salinas CA; Chaves H; Guindy R; Chopra P; Moller RA; Schou IM;
J Hum Hypertens; 2009 Mar; 23(3):196-210. PubMed ID: 18800143
[TBL] [Abstract][Full Text] [Related]
30. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
31. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
Koren MJ; Hunninghake DB;
J Am Coll Cardiol; 2004 Nov; 44(9):1772-9. PubMed ID: 15519006
[TBL] [Abstract][Full Text] [Related]
34. Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients.
Yamada S; Yanagawa T; Sasamoto K; Araki A; Miyao M; Yamanouchi T
Metabolism; 2006 Jan; 55(1):67-71. PubMed ID: 16324921
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
[TBL] [Abstract][Full Text] [Related]
36. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
Farsang C; Athyros V; Gaw A;
Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
[TBL] [Abstract][Full Text] [Related]
37. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.
Jones PH; McKenney JM; Karalis DG; Downey J
Am Heart J; 2005 Jan; 149(1):e1. PubMed ID: 15660024
[TBL] [Abstract][Full Text] [Related]
39. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.
Hunninghake D; Bakker-Arkema RG; Wigand JP; Drehobl M; Schrott H; Early JL; Abdallah P; McBride S; Black DM
J Fam Pract; 1998 Nov; 47(5):349-56. PubMed ID: 9834769
[TBL] [Abstract][Full Text] [Related]
40. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
BayƩs B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]